Adalvo is well positioned for Day-1 launches of their generic Tafamidis 61mg soft gel capsules, supported by strong development and IP strategy.
Based on the reference brand Vyndamax, Tafamidis is indicated for Hereditary Transthyretin-Related Amyloidosis Cardiomyopathy (ATTR-CM), a serious and progressive condition in which abnormal protein deposits accumulate in the heart, impairing its function over time.
Improvements in clinical awareness mean that patient numbers are rising steadily. As the only approved single-capsule, once-daily oral treatment for ATTR-CM, Tafamidis is one of the world’s most commercially significant rare disease therapies.
According to IQVIA, global sales reached $9.04bn in 2025 — up from $3.85bn in 2023, representing growth of more than 130% over two years.
To explore licensing and commercial opportunities for Tafamidis, contact our team.
Adalvo has been building towards Day-1 launches in key European markets. The CP and DCP submission process has been navigated with precision, reflecting the exceptional quality of its Tafamidis dossier.
With a robust IP strategy in place, Adalvo is one of the few pharmaceutical companies with the technical capability and commercial readiness to deliver a partner-ready asset at launch.
For partners seeking a first-mover advantage in key European markets, the opportunity is real and the time is nearing.
To discuss licensing or partnership opportunities, get in touch with the team today.